In vitro antibacterial activity of dinuclear thiolato-bridged ruthenium(II)-arene compounds

Microbiol Spectr. 2023 Dec 12;11(6):e0095423. doi: 10.1128/spectrum.00954-23. Epub 2023 Oct 10.

Abstract

The in vitro assessment of diruthenium(II)-arene compounds against Escherichia coli, Streptococcus pneumoniae, and Staphylococcus aureus showed a significant antibacterial activity of some compounds against S. pneumoniae, with minimum inhibitory concentration (MIC) values ranging from 1.3 to 2.6 µM, and a medium activity against E. coli, with MIC of 25 µM. The nature of the substituents anchored on the bridging thiols and the compounds molecular weight appear to significantly influence the antibacterial activity. Fluorescence microscopy showed that these ruthenium compounds enter the bacteria and do not accumulate in the cell wall of gram-positive bacteria. These diruthenium(II)-arene compounds exhibit promising activity against S. aureus and S. pneumoniae and deserve to be considered for further studies, especially the compounds bearing larger benzo-fused lactam substituents.

Keywords: Escherichia coli; ICP-MS; MIC; Staphylococcus aureus; Streptococcus pneumoniae; benzo-fused lactams; fluorescence; ruthenium complexes; uptake.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Escherichia coli
  • Humans
  • Microbial Sensitivity Tests
  • Ruthenium* / pharmacology
  • Staphylococcal Infections*
  • Staphylococcus aureus
  • Streptococcus pneumoniae

Substances

  • Ruthenium
  • Anti-Bacterial Agents